JP2020500872A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020500872A5 JP2020500872A5 JP2019529251A JP2019529251A JP2020500872A5 JP 2020500872 A5 JP2020500872 A5 JP 2020500872A5 JP 2019529251 A JP2019529251 A JP 2019529251A JP 2019529251 A JP2019529251 A JP 2019529251A JP 2020500872 A5 JP2020500872 A5 JP 2020500872A5
- Authority
- JP
- Japan
- Prior art keywords
- agent according
- inhibitor
- complex agent
- complex
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 claims 39
- 239000003112 inhibitor Substances 0.000 claims 11
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 claims 8
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims 8
- 208000034578 Multiple myelomas Diseases 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- JFUAWXPBHXKZGA-IBGZPJMESA-N 4-fluoro-2-[(4r)-5,5,5-trifluoro-4-hydroxy-2-methyl-4-(1h-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-yl]phenol Chemical compound C([C@@](O)(CC=1NC2=CN=CC=C2C=1)C(F)(F)F)C(C)(C)C1=CC(F)=CC=C1O JFUAWXPBHXKZGA-IBGZPJMESA-N 0.000 claims 2
- 229940124291 BTK inhibitor Drugs 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229960001467 bortezomib Drugs 0.000 claims 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 2
- 229960002438 carfilzomib Drugs 0.000 claims 2
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 claims 2
- 108010021331 carfilzomib Proteins 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 229960003957 dexamethasone Drugs 0.000 claims 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 2
- 229940124750 glucocorticoid receptor agonist Drugs 0.000 claims 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 2
- 229960004942 lenalidomide Drugs 0.000 claims 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 2
- -1 maphosphamide Chemical compound 0.000 claims 2
- 229960000688 pomalidomide Drugs 0.000 claims 2
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims 2
- 239000003207 proteasome inhibitor Substances 0.000 claims 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 2
- 229960004528 vincristine Drugs 0.000 claims 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 1
- 101100004408 Arabidopsis thaliana BIG gene Proteins 0.000 claims 1
- 239000012664 BCL-2-inhibitor Substances 0.000 claims 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- 101100485279 Drosophila melanogaster emb gene Proteins 0.000 claims 1
- 102100029095 Exportin-1 Human genes 0.000 claims 1
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 claims 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 239000012828 PI3K inhibitor Substances 0.000 claims 1
- 101100485284 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CRM1 gene Proteins 0.000 claims 1
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 claims 1
- 102100038183 Tyrosine-protein kinase SYK Human genes 0.000 claims 1
- 101150094313 XPO1 gene Proteins 0.000 claims 1
- 229960002707 bendamustine Drugs 0.000 claims 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229960000684 cytarabine Drugs 0.000 claims 1
- 229940126590 dalatumumab Drugs 0.000 claims 1
- 229960002204 daratumumab Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229960004137 elotuzumab Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- 108700002148 exportin 1 Proteins 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 229960001507 ibrutinib Drugs 0.000 claims 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229950007752 isatuximab Drugs 0.000 claims 1
- 229960003648 ixazomib Drugs 0.000 claims 1
- MXAYKZJJDUDWDS-LBPRGKRZSA-N ixazomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MXAYKZJJDUDWDS-LBPRGKRZSA-N 0.000 claims 1
- 229940124302 mTOR inhibitor Drugs 0.000 claims 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 1
- 229960001924 melphalan Drugs 0.000 claims 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 229960005184 panobinostat Drugs 0.000 claims 1
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims 1
- 229960005205 prednisolone Drugs 0.000 claims 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 229960003433 thalidomide Drugs 0.000 claims 1
- 230000035899 viability Effects 0.000 claims 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims 1
- 229960000237 vorinostat Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022192010A JP2023022228A (ja) | 2016-12-02 | 2022-11-30 | 癌を処置するための併用療法 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662429612P | 2016-12-02 | 2016-12-02 | |
| US62/429,612 | 2016-12-02 | ||
| US201762444326P | 2017-01-09 | 2017-01-09 | |
| US62/444,326 | 2017-01-09 | ||
| US201762466968P | 2017-03-03 | 2017-03-03 | |
| US62/466,968 | 2017-03-03 | ||
| US201762530781P | 2017-07-10 | 2017-07-10 | |
| US62/530,781 | 2017-07-10 | ||
| US201762567542P | 2017-10-03 | 2017-10-03 | |
| US62/567,542 | 2017-10-03 | ||
| PCT/US2017/064222 WO2018102687A2 (en) | 2016-12-02 | 2017-12-01 | Combination therapy for treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022192010A Division JP2023022228A (ja) | 2016-12-02 | 2022-11-30 | 癌を処置するための併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020500872A JP2020500872A (ja) | 2020-01-16 |
| JP2020500872A5 true JP2020500872A5 (https=) | 2021-01-14 |
| JP7208898B2 JP7208898B2 (ja) | 2023-01-19 |
Family
ID=60991504
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019529251A Active JP7208898B2 (ja) | 2016-12-02 | 2017-12-01 | 癌を処置するための併用療法 |
| JP2022192010A Pending JP2023022228A (ja) | 2016-12-02 | 2022-11-30 | 癌を処置するための併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022192010A Pending JP2023022228A (ja) | 2016-12-02 | 2022-11-30 | 癌を処置するための併用療法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20200078362A1 (https=) |
| EP (1) | EP3548032A2 (https=) |
| JP (2) | JP7208898B2 (https=) |
| AU (2) | AU2017367768A1 (https=) |
| WO (1) | WO2018102687A2 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3363B1 (ar) | 2011-04-13 | 2019-03-13 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| CA3025933A1 (en) | 2016-06-01 | 2017-12-07 | Epizyme, Inc. | Use of ezh2 inhibitors for treating cancer |
| WO2018183885A1 (en) | 2017-03-31 | 2018-10-04 | Epizyme, Inc. | Combination therapy for treating cancer |
| AU2018275123A1 (en) | 2017-06-02 | 2020-01-30 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
| CN111093660A (zh) | 2017-09-05 | 2020-05-01 | Epizyme股份有限公司 | 用于治疗癌症的组合疗法 |
| US20220362254A1 (en) * | 2019-08-22 | 2022-11-17 | Thomas Jefferson University | Methods for reprogramming cancer cells |
| WO2021063332A1 (zh) * | 2019-09-30 | 2021-04-08 | 江苏恒瑞医药股份有限公司 | 一种ezh2抑制剂与cdk4/6抑制剂联合在制备治疗肿瘤药物中的用途 |
| US20220395575A1 (en) * | 2019-11-14 | 2022-12-15 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Combination therapy with protein kinase b activation inhibitor to treat cancer |
| WO2023111810A1 (en) * | 2021-12-14 | 2023-06-22 | Pfizer Inc. | Combination therapies and uses for treating cancer |
| WO2024106879A1 (ko) * | 2022-11-17 | 2024-05-23 | 인제대학교 산학협력단 | Ezh2 저해제 및 btk 억제제를 포함하는, 암의 예방 또는 치료용 약제학적 조성물 |
| KR20250088372A (ko) * | 2023-12-08 | 2025-06-17 | 인제대학교 산학협력단 | Btk 분해제와 mettl3 억제제를 포함하는 암의 예방 또는 치료용 약제학적 조성물 |
| WO2025166537A1 (en) * | 2024-02-06 | 2025-08-14 | Epizyme, Inc. | Methods of treatment using an ezh2 modulator |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US7229774B2 (en) | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
| UA110112C2 (uk) | 2010-05-07 | 2015-11-25 | Глаксосмітклайн Ллс | Індоли |
| BR112013005806B1 (pt) | 2010-09-10 | 2022-05-10 | Epizyme, Inc | Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2 |
| JO3363B1 (ar) | 2011-04-13 | 2019-03-13 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| NZ628762A (en) | 2012-02-10 | 2016-07-29 | Constellation Pharmaceuticals Inc | Modulators of methyl modifying enzymes, compositions and uses thereof |
| SI2953941T1 (sl) | 2013-02-11 | 2017-08-31 | Constellation Pharmaceuticals, Inc. | Modulatorji metil-modificirajočih encimov, sestavki in uporabe le-teh |
| US9603927B2 (en) * | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| EP3119390A4 (en) * | 2014-03-21 | 2017-09-20 | Glaxosmithkline Intellectual Property (No. 2) Limited | Methods of treating cancer |
| US9717745B2 (en) * | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
| CA3025933A1 (en) * | 2016-06-01 | 2017-12-07 | Epizyme, Inc. | Use of ezh2 inhibitors for treating cancer |
-
2017
- 2017-12-01 JP JP2019529251A patent/JP7208898B2/ja active Active
- 2017-12-01 WO PCT/US2017/064222 patent/WO2018102687A2/en not_active Ceased
- 2017-12-01 AU AU2017367768A patent/AU2017367768A1/en not_active Abandoned
- 2017-12-01 US US16/465,736 patent/US20200078362A1/en not_active Abandoned
- 2017-12-01 EP EP17829746.1A patent/EP3548032A2/en not_active Withdrawn
-
2022
- 2022-11-30 JP JP2022192010A patent/JP2023022228A/ja active Pending
-
2024
- 2024-01-08 AU AU2024200112A patent/AU2024200112A1/en not_active Abandoned
- 2024-01-12 US US18/411,139 patent/US20240293418A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020500872A5 (https=) | ||
| FI3651766T3 (fi) | 4-(4-(4-(((2-(2,6-dioksopiperidin-3-yyli)-l-oksoisoindolin-4-yyli)oksi)metyyli)bentsyyli)piperatsin-1-yyli)-3-fluoribentsonitriili antiproliferatiivisena yhdisteenä | |
| EP3842442B1 (en) | Compositions and methods for inhibiting arginase activity | |
| Bringhen et al. | New agents in multiple myeloma: an examination of safety profiles | |
| EP4442695A3 (en) | 19-homo, 3.alpha.-hydroxy-steroid-20-one compounds for treating cns disorders | |
| JP2017008088A5 (https=) | ||
| JP2019514854A5 (https=) | ||
| JP2017048208A5 (https=) | ||
| JP2017518334A5 (https=) | ||
| BR122020022275B1 (pt) | Composto inibidor de arginase, composição farmacêutica e uso do referido composto na fabricação de uma composição farmacêutica para o tratamento de cancêr | |
| PE20142101A1 (es) | Composiciones farmaceuticas de aliskiren | |
| RU2018137687A (ru) | Фармацевтические комбинации для лечения злокачественной опухоли | |
| WO2015034678A3 (en) | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis | |
| JP2014114295A5 (https=) | ||
| PE20181523A1 (es) | Tratamiento de lupus nefritis usando laquinimod | |
| JP2016514148A5 (https=) | ||
| CL2009000662A1 (es) | Compuestos derivados de 1,2,4-triazol trisustituidos, moduladores del receptor de acetilcolina nicotinicos; composicion farmaceutica; su proceso de preparacion; y uso para la prevencion o el tratamiento de trastornos psicoticos, trastornos o enfermedades de daño intelectual, o enfermedades o trastornos inflamatorios. | |
| JP2016523260A5 (https=) | ||
| JP2017503842A5 (https=) | ||
| JP2011520846A5 (https=) | ||
| NO20091185L (no) | Piperidinderivater | |
| JP2018503610A5 (https=) | ||
| CO6460746A2 (es) | Tratamiento de trastornos cognitivos con determinados receptores de ácido nicotínico alfa-7 en combinación con inhibidores de acetilcolinesterasa | |
| MA44935A1 (fr) | Compositions pharmaceutiques contenant un antagoniste de l'intégrine alpha 4 , utilisée pour le traitement d"affections inflammatoires oculaires | |
| AR096045A1 (es) | Composición farmacéutica y formulación para prevenir o tratar el síndrome de ojo seco |